Propanc Biopharma, Inc. - Common Stock (NQ:PPCB)

0.1095 -0.0036 (-3.18%)

Streaming Delayed Price Updated: 11:11 AM EDT, Apr 22, 2026 Add to My Watchlist

Price and Volume

Volume	911,739
Open	0.1130
Bid (Size)	0.1061 (5,000)
Ask (Size)	0.1096 (500)
Prev. Close	0.1131
Today's Range	0.1056 - 0.1150
52wk Range	0.0950 - 1.980
Shares Outstanding	15,859,280
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

These stocks are moving in today's after hours session ↗

April 17, 2026

Via Chartmill

Rosen Law Firm Encourages Propanc Biopharma Inc. Investors to Inquire About Securities Class Action Investigation – PPCB

April 16, 2026

From The Rosen Law Firm, P.A.

Via Business Wire

Performance

YTD	-80.8%	-80.8%
1 Month	-7.0%	-7.0%
3 Month	-63.4%	-63.4%
6 Month	-93.1%	-93.1%
1 Year	-93.8%	-93.8%

More News

Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain

March 24, 2026

From Propanc Biopharma, Inc.

Via GlobeNewswire

Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy

March 12, 2026

From Propanc Biopharma, Inc.

Via GlobeNewswire

Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study

March 10, 2026

From Propanc Biopharma, Inc.

Via GlobeNewswire

Propanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models

March 03, 2026

From Propanc Biopharma, Inc.

Via GlobeNewswire

Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results

February 18, 2026

From Propanc Biopharma, Inc.

Via GlobeNewswire

Wondering what's happening in today's after-hours session? ↗

February 16, 2026

Via Chartmill

Unusual volume stocks in Friday's session ↗

February 06, 2026

Via Chartmill

Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market

February 05, 2026

From Propanc Biopharma, Inc.

Via GlobeNewswire

Top movers in Thursday's session ↗

January 29, 2026

Via Chartmill

Thursday's session: gap up and gap down stocks ↗

January 29, 2026

Via Chartmill

These stocks that are showing activity before the opening bell on Thursday. ↗

January 29, 2026

Via Chartmill

Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations

January 27, 2026

From Propanc Biopharma, Inc.

Via GlobeNewswire

Which stocks are moving after the closing bell on Friday? ↗

January 23, 2026

Via Chartmill

Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia

January 20, 2026

From Propanc Biopharma, Inc.

Via GlobeNewswire

Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer

January 15, 2026

From Propanc Biopharma, Inc.

Via GlobeNewswire

Propanc Biopharma Provides Shareholder Update

January 13, 2026

From Propanc Biopharma, Inc.

Via GlobeNewswire

Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal

December 22, 2025

From Propanc Biopharma, Inc.

Via GlobeNewswire

Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs

December 04, 2025

From Propanc Biopharma, Inc.

Via GlobeNewswire

What's going on in today's session ↗

December 01, 2025

Via Chartmill

Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis

December 01, 2025

From Propanc Biopharma, Inc.

Via GlobeNewswire

Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results

November 17, 2025

From Propanc Biopharma, Inc.

Via GlobeNewswire

Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company’s R&D Pipeline

November 10, 2025

From Propanc Biopharma, Inc.

Via GlobeNewswire

Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)

November 04, 2025

From Propanc Biopharma, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Propanc Biopharma, Inc. - Common Stock publicly traded?

Yes, Propanc Biopharma, Inc. - Common Stock is publicly traded.

What exchange does Propanc Biopharma, Inc. - Common Stock trade on?

Propanc Biopharma, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Propanc Biopharma, Inc. - Common Stock?

The ticker symbol for Propanc Biopharma, Inc. - Common Stock is PPCB on the Nasdaq Stock Market

What is the current price of Propanc Biopharma, Inc. - Common Stock?

The current price of Propanc Biopharma, Inc. - Common Stock is 0.1095

When was Propanc Biopharma, Inc. - Common Stock last traded?

The last trade of Propanc Biopharma, Inc. - Common Stock was at 04/22/26 11:11 AM ET

What is the market capitalization of Propanc Biopharma, Inc. - Common Stock?

The market capitalization of Propanc Biopharma, Inc. - Common Stock is 1.74M

How many shares of Propanc Biopharma, Inc. - Common Stock are outstanding?

Propanc Biopharma, Inc. - Common Stock has 2M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.